Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
VXA-CoV2-1 · 1 trial · 1 indication
Subject reported symptoms of local and systemic reactogenicity
Subject reported symptoms of local and systemic reactogenicity
Any adverse events observed or reported following vaccination
Any adverse events observed or reported following vaccination
Any adverse events reported following vaccination meeting definition of serious
Any adverse events reported following vaccination meeting definition of serious
| Arm | Type | Description |
|---|---|---|
| Low Dose VXA-CoV2-1 | EXPERIMENTAL | Low dose (1E10 I.U.) of VXA-CoV2-1 oral tableted vaccine dispensed at Day 1. A subset will also receive a second dose at Day 29 |
| High Dose | EXPERIMENTAL | High Dose (1E11 I.U.) of VXA-CoV2-1 oral tableted vaccine dispensed at Day 1 |
| Name | Type | Description |
|---|---|---|
| VXA-CoV2-1 | BIOLOGICAL | non replicating Ad5 adjuvanted oral tableted vaccine |
Inclusion Criteria: 1. Male or female between the ages of 18 to 54 years, inclusive. 2. Negative for SARS-CoV-2 infection at the time of screening 3. In generally good health, without significant medical illness 4. Demonstrates comprehension of the protocol procedures and is able to provide written...